Brief: Mabion Expands And Extends Deal With Novavax Till End-2026

Mabion SA

23/09/2022 07:06

Sept 23 (Reuters) - Mabion SA  MABP.WA :
    * SAID ON THURSDAY IT HAS SIGNED ANNEX TO DEAL WITH NOVAVAX
FOR
CONTRACTED COMMERCIAL PRODUCTION AS WELL AS ANNEX TO COMMERCIAL
SCALE PRODUCTION DEAL OF ANTIGEN TO COVID-19 VACCINE UNDER NAME
OF NVX-COV2373 
    * UNDER ANNEX, NOVAVAX HAS ALSO COMMITTED TO TAKE ACTIONS
AIMING
AT IMMEDIATELY ORDERING COMPANY TO USE MANUFACTURING SLOT TO
PRODUCE AN AGREED BY PARTIES SERIES OF ANTIGEN FOR OMICRON
VARIANT OF COVID-19 VACCINE, INCLUDING TRANSFER OF TECHNOLOGY
    * UNDER ANNEX, BASED ON SCHEDULE SET BY PARTIES, COMPANY
WILL
RECEIVE REMUNERATION FOR PRODUCTION OF SERIES OF PRODUCT OR
REMUNERATION FOR CAPABILITY TO MANUFACTURE PRODUCT BASED ON
PRODUCTION FORCE GUARANTEED TO NOVAVAX 
    * DURATION OF DEAL HAS BEEN EXTENDED TILL END OF 2026

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM14HlXta
 Further company coverage:  MABP.WA  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))